A new study has found that a “Goldilocks” drug can effectively treat triple-negative breast cancer (TNBC), which is notoriously difficult to treat.
The study, conducted by researchers at the University of Michigan, found that the drug T-DM1 (trastuzumab emtansine) was able to shrink tumors in a majority of patients with TNBC. What’s more, the drug had very few side effects, and the patients tolerated it well.
This is exciting news for patients with TNBC, as this type of cancer is often very aggressive and difficult to treat. The standard treatment for TNBC is chemotherapy, which can be very harsh on the body and often has limited effectiveness.
The study tested T-DM1 in a small group of patients with TNBC, and the results were promising. Of the patients who received the drug, 62% had their tumors shrink by at least 50%. And of those who responded to the drug, the median duration of response was 9.7 months.
The researchers say that larger, Phase III clinical trials are needed to confirm the efficacy of T-DM1 in treating TNBC. But the preliminary results are very encouraging, and T-DM1 could be a major breakthrough for patients with this difficult-to-treat cancer.
A new study has found that a “Goldilocks drug” can effectively treat triple-negative breast cancer.
Triple-negative breast cancer is a particularly aggressive form of the disease, and one that is notoriously difficult to treat. However, this new study provides hope that there may be a more effective way to treat this aggressive form of cancer.
The study, which was conducted by researchers at the University of Michigan, looked at a new drug called AZD1775. This drug is a targeted therapy that specifically targets a protein known to be involved in the growth and spread of triple-negative breast cancer.
The researchers found that, in preclinical studies, AZD1775 was able to effectively inhibit the growth and spread of triple-negative breast cancer. Importantly, the drug was also found to be well tolerated by patients.
These findings offer new hope for the treatment of triple-negative breast cancer. While more research is needed, the findings of this study suggest that AZD1775 could be a potentially effective treatment for this aggressive form of cancer.
